Board Decision
FEB
3/23/04

wherein:

X is selected from $-CH_2-$ or a chemical bond;

Y is selected from $-(CH_2)_m-$ or $-(CH_2)-O-(CH_2)-$;

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

B1

$R_1$ and $R_2$ are independently selected from the group consisting of aryl, monocyclic heteroaryl having 5 – 6 ring atoms of which 1-3 ring atoms are independently selected from the group consisting of N, S and O, and bicyclic heteroaryl having a phenyl ring fused to a monocyclic heteroaryl ring as defined above, optionally substituted with F, Cl, Br, I, -OH, $-NH_2$, $-CO_2H$, $-CO_2-C_1-C_6$ alkyl, -CN, $-NO_2$, $C_1-C_6$ alkyl, $C_2-C_6$ alkenyl, $C_2-C_6$ alkynyl, $C_1-C_6$ perhaloalkyl, $OR_3$, or $C_1-C_6$ perhaloalkoxy;

$R_3$ is selected from the group consisting of H, $C_1-C_6$ alkyl, $C_2-C_6$ alkenyl, $C_2-C_6$ alkynyl, $C_6-C_{10}$ aryl, monocyclic heteroaryl having 5 –6 ring atoms of which 1-3 ring atoms are independently selected from the group consisting of N, S and O, and bicyclic heteroaryl having a phenyl ring fused to a monocyclic heteroaryl ring as defined above, $C_7-C_{14}$ aralkyl, and mono or bicyclic heteroaralkyl consisting of a $C_1-C_4$ alkyl having a substituent which is a mono or bicyclic heteroaryl as defined above, where the aryl or heteroaryl group is optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, $-NH_2$, $-NO_2$, -OH, alkyl, $C_2-C_6$ alkenyl, $C_2-C_6$ alkynyl, $C_1-C_6$ perhaloalkyl, $C_1-C_6$ alkoxy, and $C_1-C_6$ perhaloalkoxy; and the optical isomers or a pharmaceutically acceptable salt thereof.

5. The compound (R)-Phenylalanine-N-[4-(phenylmethyl)-1-piperazinyl]carboxamide Dihydrochloride.

B2

6. The compound (R)-[1-(Phenylmethyl)-2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amine.

B3

13. The compound (R)-[1-(Phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]-carbamic acid tert-butyl ester.

Cancel claims 17-25 and 31-38 without prejudice.